Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 15/20 | 0.53 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22843644 | 0.94 | NT5E (0.52) | NT5ECDK1CCNB1 | |
| SCHEMBL22843625 | 0.94 | NT5E (0.52) | NT5ECDK1CDK2CCNB1CCNE1 | |
| SCHEMBL22843485 | 0.93 | NT5E (0.47) | NT5ECDK1CDK2CCNE1CDK5 | |
| SCHEMBL22843500 | 0.91 | NT5E (0.51) | NT5E | |
| SCHEMBL22843623 | 0.90 | NT5E (0.54) | NT5ECDK1CDK2CDK9 | |
| SCHEMBL22843666 | 0.89 | NT5E (0.49) | NT5ECDK1CDK2CDK9 | |
| SCHEMBL22843509 | 0.89 | NT5E (0.47) | NT5ECDK1CDK2CDK9 | |
| SCHEMBL22843541 | 0.88 | NT5E (0.48) | NT5E | |
| SCHEMBL22843530 | 0.88 | NT5E (0.51) | NT5E | |
| SCHEMBL22843655 | 0.88 | NT5E (0.46) | NT5ECDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | ARCUS BIOSCIENCES, INC. | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405629-A1 | PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS | NT5C2, ADA, ENTPD1 | NT5E 10/4885CDK1 4327/4885CDK2 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.